• Ziprasidone HCl: Mechanisms and Research Benchmarks

  2026-09-12

  Ziprasidone HCl combines established serotonin–dopamine receptor pharmacology with reported GOT1 inhibition in pancreatic cancer models. This article separates clinical neuropsychiatric use from preclinical oncology evidence and organizes assay, formulation, and dosing parameters for reproducible research.

• Alternariol (AOH): Mechanisms & Research Workflow

  2026-09-11

  Alternariol, also called AOH, is an emerging Alternaria mycotoxin with documented effects on steroid secretion, cell viability, apoptosis, cytoskeletal proteins, and hepatic stellate-cell activation. This article separates established product and literature findings from practical assay recommendations for mycotoxin research, cytochrome P450 enzyme assays, and apoptosis mechanism research.

• Lactate–HMGB1 Signaling in Polymicrobial Sepsis

  2026-09-11

  The reference study identifies lactate as an active regulator of macrophage HMGB1 modification and exosomal release, rather than merely a clinical marker of sepsis severity. Its integrated cell, genetic, exosome, endothelial, and mouse experiments connect lactate transport and GPR81-associated signaling with vascular permeability and survival, offering a mechanistic framework for inflammation research.

• Early Life Adversity, Oxytocin, and Innate Fear

  2026-09-10

  This 2026 Communications Biology study links early life adversity to impaired looming-evoked defensive behavior in mice and identifies deficient oxytocin signaling in the superior colliculus as a mechanistic pathway. Its combination of developmental stress modeling, circuit analysis, receptor manipulation, and intranasal oxytocin rescue provides a framework for studying how early experience alters innate threat processing.

• ALC-0315 LNP Mixing: Workflow and Troubleshooting

  2026-09-10

  Build more reproducible mRNA lipid nanoparticles with ALC-0315 by treating mixing as a formulation variable, not merely a transfer step. This workflow connects stock handling, flow regime, physicochemical QC, and biological testing to improve the relevance of bench-scale results for therapeutic mRNA delivery.

• Triptolide and Transcriptional Stress

  2026-09-09

  Triptolide (PG490) is more than a cytotoxic natural product: it is a powerful probe of transcriptional stress, immune signaling, and tissue-barrier biology. This article connects its CDK7–RNAPII mechanism with new acute pancreatitis findings to improve assay design and interpretation.

• VX-745: p38α MAPK Inhibitor Workflows

  2026-09-09

  VX-745 combines nanomolar p38α inhibition with practical utility across cytokine, oncology, aging, and arthritis research. This guide converts its biochemical profile into reproducible cell-assay workflows, mechanistic controls, and troubleshooting strategies.

• NF 449: From P2X1 Blockade to Assay Design

  2026-09-08

  NF 449 is a potent purinergic receptor antagonist for resolving P2X1-dependent platelet signaling. This guide interprets potency across recombinant, native-cell, and thrombosis models while translating the evidence into better platelet assay design.

• Fucoidan and Cancer Plasticity: A Translational Roadmap

  2026-09-08

  Fucoidan is more than a broadly described marine polysaccharide: its apoptosis, angiogenesis, and immune-modulating activities create a useful framework for translational oncology. This article connects those findings with cancer-cell plasticity research and outlines a disciplined path from mechanistic hypothesis to reproducible model validation.

• Triptolide (PG490) Experimental Workflow

  2026-09-07

  Triptolide (PG490) is a nanomolar transcriptional perturbagen for cancer, immune, and inflammatory research. This guide translates its RNAPII, IL-2, NF-κB, MMP, and AhR–HSF1 applications into practical workflows, controls, and troubleshooting strategies.

• CB-839 Workflow for Glutamine Metabolism

  2026-09-07

  CB-839 (Telaglenastat) provides a selective, reversible way to test whether GLS1-dependent glutaminolysis supports tumor-cell growth, metabolic fitness, or stress adaptation. This workflow connects dose-response pharmacology with metabolite, apoptosis, autophagy, and RNA-regulatory readouts for stronger preclinical cancer drug evaluation.

• Ajugol, Mitophagy, and Pyroptosis in Gouty Arthritis

  2026-09-05

  The reference study identifies impaired PINK1/Parkin-dependent mitophagy as a mechanistic link between PI3K/Akt/mTOR signaling and chondrocyte pyroptosis in acute gouty arthritis. Using computational analysis, human chondrocyte models, pharmacological perturbation, and MSU-induced mice, the authors show that ajugol protects cartilage by restoring mitochondrial quality control and limiting NLRP3 inflammasome activation.

• Recombinant Human Oncostatin M in Fibrosis Assays

  2026-09-04

  Recombinant Human Oncostatin M provides a defined cytokine perturbation for dissecting inflammatory and fibroproliferative circuits. This guide connects rh-Oncostatin M with mast cell–mesothelial crosstalk research while separating established findings from testable assay hypotheses.

• From NEXMIF Biology to qPCR Translation

  2026-09-04

  A translational framework for using targeted qPCR to validate NEXMIF dosage biology, connect transcriptomic findings with neuronal phenotypes, and build more reproducible gene expression workflows with HotStart™ Universal 2X Green qPCR Master Mix.

• Pam3CSK4 TFA for TLR1/2 Assays

  2026-09-03

  Pam3CSK4 TFA provides a defined, tunable trigger for separating TLR1/2-driven cytokine responses from the broader complexity of bacterial stimulation. This guide translates maternal–neonatal biomarker findings into practical assay design, stock handling, controls, optimization, and translational workflows.

8484 records 1/566 page Next 12345 下5页 Last page